CRO Services

Drug Development Expertise Empowering Research Services for Biologics

T Cell Engager (TCE): Mechanisms, Applications, and Development Considerations

Advancing TCE discovery with rigorous science and translational-driven insights

T cell engagers (TCEs) are bispecific antibodies designed to bind a tumor-associated antigen on cancer cells and the CD3 receptor on T cells. Common formats include compact BiTE®-like (Blinatumomab, Amgen ) molecules and IgG-like bispecific antibodies. By physically linking T cells to target cells, TCEs enable MHC-independent recognition and direct, antigen-dependent cytotoxicity. Their capacity to form an immune synapse and drive serial T cell killing has placed TCEs at the forefront of targeted immunotherapy research.

Current research focuses on optimizing T cell engager format, binding affinity, efficacy, safety, manufacturability, and pharmacokinetics to support use across hematologic malignancies and solid tumors. Key development considerations include cytokine release, sensitivity to target antigen density, and translational PK/PD relationships. These efforts aim to improve the therapeutic index of bispecific T cell engagers through better dose control, durable responses, and scalable production.

If you are exploring TCE design or planning early discovery work, you are welcome to discuss it with us or read the following sections that offer a concise guide to key considerations shaping successful development.

Expert-Guided T Cell Engager Discovery & Engineering Mechanism-Based TCE Efficacy & Safety Testing Navigating Key Challenges in TCE Discovery

Start a Conversation

Illustration of a bispecific T cell engager bridging a T cell and a tumor cell to form an immune synapse and drive targeted cytotoxicity

Expert-Guided T Cell Engager Discovery and Engineering

As T cell engagers continue to expand in immuno-oncology, their success depends on careful molecular design that balances potency, selectivity, cytokine release syndrome (CRS), and manufacturability. Because generating a new anti-CD3 binder is technically challenging and rarely necessary, most bispecific T cell engager programs adopt a validated CD3 arm and focus discovery efforts on identifying the optimal tumor-associated antigen (TAA) antibody and configuring the overall bispecific architecture.

Up to date list of approved T-cell engager therapies, including targets, indications, and approval status, summarized in a clear visual reference.

TAA-Binding Arm: Designing an effective T cell engager (TCE) begins with rational selection of the TAA-binding arm based on target biology, epitope accessibility, binding specificity, tumor selectivity, and optimized avidity. To identify the appropriate anti-TAA building block, developers typically use multiple antibody discovery approaches, including hybridoma, naïve or synthetic libraries, VHH scaffolds, and single B-cell platforms. These methods enable access to diverse epitopes with structural and functional properties suitable for balanced T cell redirection, allowing fine tuning of the TAA arm while leveraging an established CD3-binding domain.

Following anti-TAA lead identification, affinity maturation, humanization, and Fc engineering may be applied as needed to further optimize binding properties, safety, and developability for downstream expression and purification.

Because no single discovery platform is suitable for all target modalities, successful bispecific T cell engager programs often rely on two or more complementary platforms. Equally important is the informed selection of the most appropriate approach based on target biology rather than platform availability alone. At the lead optimization stage, careful interpretation of affinity, functional, and early developability data in a development context rather than in isolation is critical for advancing viable TCE candidates.

Bispecific Architecture: When designing bispecific antibody (bsAb) formats for T cell engagers, factors such as valency, epitope geometry, synapse distance, CD3-arm affinity, and overall molecular architecture (BiTE®-like or IgG-like) strongly influence immune synapse formation, T cell activation, cytokine release behavior, pharmacokinetics, antigen-density sensitivity, and the achievable therapeutic window.

Schematic of bispecific antibody architectures for T cell engagers, illustrating how format, valency, epitope geometry, and synapse distance are considered in molecular design

Expression and Screening: Early design decisions affect downstream developability and translational feasibility, making efficient expression and screening critical for functional evaluation. Initial production systems must generate sufficient, properly assembled bispecific molecules to assess stability, chain pairing fidelity, and manufacturability. Scalable expression and purification workflows then ensure the availability of high-quality material for in vitro characterization and in vivo studies. These steps link molecular design with practical feasibility and support selection of T cell engager candidates that are suitable for further development.

Share Your Goals and Perspective with Us

How We Support T Cell Engager Discovery and Engineering

TCE discovery involves several connected steps, including target and antibody selection, format design, expression, screening, and production. Progress at this stage depends on sound molecular design, reliable expression systems, efficient screening, and materials suitable for functional testing and downstream development. With experience in antibody engineering and an understanding of later-stage requirements, we support each step of TCE discovery to help teams advance well-characterized, development-ready candidates.

Antibody Discovery

MOA-driven platform selection across hybridoma, single-B cell, and display libraries
Lead optimization via humanization, affinity maturation, and Fc engineering
Proven expertise across 650+ discovery, 20+ clinical-stage, and 2 marketed programs

Format Design & Engineering

Format design guided by an early-stage developability mindset
Data-driven pair and format selection via in silico, biophysical, and functional analyses
Early-stage developability assessment to reduce late-stage CMC risks

Quick ‘n’ Clean BsAb Production

High-throughput small-scale bsAb production
Unlock the optimal bsAb pairings in a fast and cost-effective way
Flexible tagged and tag-free construct options

Premium BsAb Production

High-titer, high-heterodimer purity, low-endotoxin bsAbs across diverse formats
LC-MS-assisted mispairing and impurity control with unmatched reliability
Market-leading scale with 6,500+ molecules annually and 100+ progressed to CMC

Case Study: High-Throughput Bispecific Production Enables Screening of Optimal T Cell Engager Antibody Pairs

Using the Quick ’n’ Clean high-throughput production, multiple TCE candidates were generated by pairing TAA antibodies from different epitope bins with a common anti-CD3 arm. This approach allowed systematic evaluation of geometry, epitope positioning, and antibody pairing effects on functional activity. Subsequent T Cell killing assays showed clear differences in potency across antibody and format combinations, enabling efficient identification of higher-performing leads.

Quick ’n’ Clean workflow enabling high-throughput screening of bispecific T cell engagers

Discuss TCE Discovery with Us

Mechanism-Based TCE Efficacy & Safety Testing

In Vitro TCE Assays

In vitro studies define how a TCE interacts with its targets and triggers immune activation. For TCE, mechanism-of-action (MOA)-driven assays are used to confirm coordinated binding to CD3 and the tumor antigen and to understand how these interactions translate into functional activity and safety signals. Core TCE in vitro assays typically assess dual binding, tumor cell killing potency, cytokine release, and T cell activation and exhaustion. Together, these readouts provide mechanistic insight into effector function, response quality, and early risk, supporting TCE optimization and translational decision-making.

Core MOA-Driven TCE Assays:

◇ TCE Dual-Binding Assay: Confirms simultaneous engagement of CD3 and the tumor antigen such as ELISA, SPR, or reporter gene assay (RGA)
◇ T Cell Killing: TDCC (T Cell–Dependent Cytotoxicity) measures tumor-cell killing potency as a primary indicator of functional activity
◇ Cytokine Release: Characterizes effector function and identifies cytokine-release risk signals (e.g., IFN-γ vs IL-6)
◇ T Cell Activation & Exhaustion: Tracks early activation (CD25, CD69) and exhaustion (PD-1, LAG-3) to evaluate response quality

Diagram illustrating the mechanism of action of a T cell engager...

In Vivo Pharmacology for TCE

In vivo pharmacology for T cell engagers use fit-for-purpose models to support coordinated evaluation of safety, exposure, and efficacy. Representative assay panels are outlined below.

◇ PK/PD: Integrated exposure and pharmacodynamic assessments combining ELISA-based PK, flow cytometric immune monitoring, and LC-MS-assisted analyses to characterize biodistribution and functional activity over time.
◇ Efficacy: Mechanism-aligned studies using appropriate in vivo models, including CDX, syngeneic, and IVIS imaging–enabled tumor models, as well as selected autoimmune and metabolic disease models, to assess T cell mediated activity.
◇ Toxicology: Evaluation of systemic immune activation using cytokine profiling and clinical pathology to identify safety-relevant signals.
◇ Immunohistology: Tissue-level characterization supported by standardized staining methods and digital pathology analysis.

These coordinated studies anchor in rationale-driven model selection and streamlined workflows to support timely, data-informed decision-making.

Overview of a preclinical in vivo pharmacology study platform for T cell engagers integrating toxicology, PK/PD and efficacy.

Discuss TCE Assays with Us

How We Can Help TCE In Vitro and In Vivo Studies

Advancing a T cell engager requires precise functional evaluation, from confirming target engagement to understanding immune activation, exposure, and safety in relevant biological systems. Our integrated in vitro and in vivo platforms combine deep assay-development expertise, specialized pharmacology models, and advanced analytical capabilities to generate mechanistic, translatable data that support confident lead-selection and development ready T cell engager .

In Vitro Assays

MOA-driven TCE assay panels
Evaluation of potency, safety, response quality, and durability
Advanced functional assay design and development

In Vivo Pharmacology

Integrated, fit-for-purpose platforms across species
NHP PK/PD/Tox studies within 6-11 weeks
Science-driven efficacy models for oncology, immunology, metabolism, etc.

Case Study: Measuring Dual-Binding, T Cell Activation, Cytokine Release, and Tumor Cell Killing in Bispecific T Cell Engagers

Bispecific T cell engagers require specialized in vitro assays to capture their true mechanism of action. Because they activate T cells through coordinated CD3 and tumor-antigen engagement, simple binding or cytotoxicity tests are not enough. A dedicated TCE assay framework measures synapse formation, tumor-cell killing, customizable cytokine release profile, T cell activation. As shown below, these assays progress from basic readouts (cell binding, TDCC) to more advanced functional models, including multiplex cytokine panels, activation/exhaustion markers, etc.

In vitro assays supporting T-cell engager optimization.

Case Study: Real-Time IncuCyte® Assay for Bispecific T Cell Engager Functional Assessment Shows Potency and Durability of TCE Activity

Real-time IncuCyte assay was used to track T cell mediated cytotoxicity over time, providing both quantitative killing kinetics and visual confirmation of tumor clearance. This more advanced dynamic readout complements TDCC and cytokine assays by revealing the potency, onset, and durability of TCE activity.

IncuCyte real-time T cell killing kinetics image.

Case Study: In Vivo Pharmacology Study in NHP Reveals Distinct PK/PD Behavior and Tissue Distribution of TCEs

Customized in vivo pharmacology studies in non-human primates (NHPs) were used to evaluate both pharmacokinetic (PK) and pharmacodynamic (PD) responses. These studies revealed a key feature of TCEs: pharmacodynamic activity does not always scale proportionally with systemic exposure. This observation highlights the importance of mechanism-aware translational modeling when interpreting PK/PD relationships for TCEs.

NHP PK/PD and tissue distribution case study image.

Case Study: Dose-Dependent TCE Efficacy and Candidate Comparison in a CDX/hPBMC Model

This CDX/hPBMC model is designed specifically for T cell engager in vivo efficacy studies. Target expression in tumors is first confirmed by IHC to ensure biological relevance. Human PBMC donors are pre-screened and qualified to provide consistent immune reconstitution and a reliable therapeutic window.

The model delivers clear, dose-dependent efficacy readouts and enables direct comparison between TCE candidates. As shown in the study, select molecules achieve stronger tumor growth inhibition than controls. This robust and reproducible platform has been used in multiple TCE programs with large pharma partners to support candidate selection and translational decisions.

CDX/hPBMC dose-dependent efficacy case study image.

Share Your Goals and Perspective with Us

Navigating Key Challenges in TCE Discovery

White paper cover on T cell engagers (TCEs) discussing key challenges and next-generation solutions from discovery to preclinical success.

Developing effective Bispecific T cell engagers requires navigating challenges across bispecific design, production, developability, and safety, particularly high-impact risks such as cytokine release syndrome (CRS). Our white paper, T cell engagers (TCEs): Challenges and Next-Gen Solutions From Discovery to Preclinical Success , navigates these key issues and presents case studies showing how comprehensive strategies help address bispecific TCE complexity, assess MOA and efficacy, and navigate clinical risks.

In this white paper, you’ll gain insight into:

Practical strategies for overcoming TCE-specific challenges, including bispecific complexity, developability and CRS risks, and tumor heterogeneity

Innovative platforms across key stages of TCE discovery (engineering, purification, characterization, etc.) to bridge discovery and translational insights

Forward-looking perspectives on integrating TCEs with immune-modulatory domains or checkpoint inhibitors
Case studies highlighting high-purity bispecific production and fit-for-purpose in vitro/in vivo evaluation that enable preclinical success

Download the White Paper to Learn More

T cell engagers are transforming how we approach targeted immunotherapy, but developing safe and effective molecules requires thoughtful design, careful engineering, scalable production, and the right functional and translational evaluations. From selecting the optimal tumor-binding arm to understanding activation, cytotoxicity, and in vivo behavior, each step plays a critical role in shaping a successful bispecific T cell engager program. If you’re exploring new TCE concepts or advancing an existing candidate, our team is here to help you navigate science and plan the next steps with confidence.

Your Project. Our Expertise.